Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient Characteristics

From: Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

  NR CVac SOC
(N = 7) (N = 29) (N = 27)
Age, years
 Mean (SD) 52.4 (10.3) 56.8 (8.5) 56.2 (9.5)
 Median (min, max) 49 (43–70) 58 (34–75) 55 (40-74)
Race, n (%)
 White 7 (100.0 %) 26 (89.7 %) 23 (85.2 %)
 Asian 0 3 (10.3 %) 2 (7.4 %)
 Black or African American 0 0 2 (7.4 %)
Ethnicity, n (%)
 Hispanic or Latino 0 0 1 (3.8 %)
 Not Hispanic or Latino 7 (100.0 %) 29 (100.0 %) 25 (96.2 %)
Cancer stage at enrollment, n (%)
 III 5 (71 %) 24 (83 %) 20 (74 %)
 IV 2 (29 %) 5 (17 %) 7 (26 %)
Histology, n (%)
 Serous 5 (71 %) 25 (86 %) 23 (85 %)
 Clear cell 1 (14 %) 0 0
 Endometrioid 0 1 (3 %) 2 (7 %)
 Mixed, serous 0 1 (3 %) 0
 Mucinous 0 1 (3 %) 1 (4 %)
 Other 1 (14 %)a 0 0
 Other, mixed 0 1 (3 %)b 1 (4 %)c
Cytoreductive Surgery
 Optimal 7 (100 %) 26 (90 %) 21 (78 %)
 Sub-optimal 0 (0 %) 3 (10 %) 6 (22 %)
  1. aAdenocarcinoma, Primary Mullerian carcinoma
  2. bLeft ovary high grade adenocarcinoma with mixed clear cell and serous features
  3. cOvarian Adenocarcinoma, Mixed Serous & Transitional cell type Grade 3: solid & focally papillary